{"url_path":"/sec/ikt/10-q/2026/item-1a","section_key":"item-1a","section_title":"Item 1A Risk Factors.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1750149/0001193125-26-219641-index.html","accession_number":"0001193125-26-219641","cik":"0001750149","ticker":"IKT","issuer_name":"Inhibikase Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1750149/0001193125-26-219641-index.html","primary_entity_key":"0001750149","primary_entity_name":"Inhibikase Therapeutics, Inc."},"word_count":81,"has_tables":true,"body_markdown":"Item 1A. Risk Factors.\n\nInvesting in our common stock involves a high degree of risk. For a detailed discussion of the risks and uncertainties related to our business, please refer to the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the Securities and Exchange Commission on March 26, 2026 (the “Annual Report”). There have been no material changes from the risk factors set forth in the Annual Report."}